|
1
|
Lowenfels AB and Maisonneuve P:
Epidemiology and prevention of pancreatic cancer. Jpn J Clin Oncol.
34:238–244. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Ward E, Brawley O and Jemal A:
Cancer statistics, 2011: The impact of eliminating socioeconomic
and racial disparities on premature cancer deaths. CA Cancer J
Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jaffee EM, Hruban RH, Biedrzycki B, Laheru
D, Schepers K, Sauter PR, Goemann M, Coleman J, Grochow L,
Donehower RC, et al: Novel allogeneic granulocyte-macrophage
colony-stimulating factor-secreting tumor vaccine for pancreatic
cancer: A phase I trial of safety and immune activation. J Clin
Oncol. 19:145–156. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Igney FH and Krammer PH: Immune escape of
tumors: Apoptosis resistance and tumor counterattack. J Leukoc
Biol. 71:907–920. 2002.PubMed/NCBI
|
|
5
|
Bernal M, Garrido P, Jiménez P, Carretero
R, Almagro M, López P, Navarro P, Garrido F and Ruiz-Cabello F:
Changes in activatory and inhibitory natural killer (NK) receptors
may induce progression to multiple myeloma: Implications for tumor
evasion of T and NK cells. Hum Immunol. 70:854–857. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nausch N and Cerwenka A: NKG2D ligands in
tumor immunity. Oncogene. 27:5944–5958. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Suzuki T, Terao S, Acharya B, Naoe M,
Yamamoto S, Okamura H and Gotoh A: The antitumour effect of
{gamma}{delta} T-cells is enhanced by valproic acid-induced
up-regulation of NKG2D ligands. Anticancer Res. 30:4509–4513.
2010.PubMed/NCBI
|
|
8
|
Groh V, Rhinehart R, Secrist H, Bauer S,
Grabstein KH and Spies T: Broad tumor-associated expression and
recognition by tumor-derived gamma delta T cells of MICA and MICB.
Proc Natl Acad Sci USA. 96:6879–6884. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Glozak MA and Seto E: Histone deacetylases
and cancer. Oncogene. 26:5420–5432. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lane AA and Chabner BA: Histone
deacetylase inhibitors in cancer therapy. J Clin Oncol.
27:5459–5468. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mann BS, Johnson JR, Cohen MH, Justice R
and Pazdur R: FDA approval summary: Vorinostat for treatment of
advanced primary cutaneous T-cell lymphoma. Oncologist.
12:1247–1252. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yagi Y, Fushida S, Harada S, Kinoshita J,
Makino I, Oyama K, Tajima H, Fujita H, Takamura H, Ninomiya I, et
al: Effects of valproic acid on the cell cycle and apoptosis
through acetylation of histone and tubulin in a scirrhous gastric
cancer cell line. J Exp Clin Cancer Res. 29:1492010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shoji M, Ninomiya I, Makino I, Kinoshita
J, Nakamura K, Oyama K, Nakagawara H, Fujita H, Tajima H, Takamura
H, et al: Valproic acid, a histone deacetylase inhibitor, enhances
radiosensitivity in esophageal squamous cell carcinoma. Int J
Oncol. 40:2140–2146. 2012.PubMed/NCBI
|
|
14
|
Franssen EJ, van Essen GG, Portman AT, de
Jong J, Go G, Stegeman CA and Uges DR: Valproic acid
toxicokinetics: Serial hemodialysis and hemoperfusion. Ther Drug
Monit. 21:289–292. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Armeanu S, Bitzer M, Lauer UM, Venturelli
S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, et
al: Natural killer cell-mediated lysis of hepatoma cells via
specific induction of NKG2D ligands by the histone deacetylase
inhibitor sodium valproate. Cancer Res. 65:6321–6329. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Poggi A, Catellani S, Garuti A, Pierri I,
Gobbi M and Zocchi MR: Effective in vivo induction of NKG2D ligands
in acute myeloid leukaemias by all-trans-retinoic acid or sodium
valproate. Leukemia. 23:641–648. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yamanegi K, Yamane J, Kobayashi K,
Kato-Kogoe N, Ohyama H, Nakasho K, Yamada N, Hata M, Nishioka T,
Fukunaga S, et al: Sodium valproate, a histone deacetylase
inhibitor, augments the expression of cell-surface NKG2D ligands,
MICA/B, without increasing their soluble forms to enhance
susceptibility of human osteosarcoma cells to NK cell-mediated
cytotoxicity. Oncol Rep. 24:1621–1627. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hidalgo M: Pancreatic cancer. N Engl J
Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu X, Rao GS, Groh V, Spies T, Gattuso P,
Kaufman HL, Plate J and Prinz RA: Major histocompatibility complex
class I-related chain A/B (MICA/B) expression in tumor tissue and
serum of pancreatic cancer: Role of uric acid accumulation in
gemcitabine-induced MICA/B expression. BMC Cancer. 11:1942011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Miyashita T, Miki K, Kamigaki T, Makino I,
Nakagawara H, Tajima H, Takamura H, Kitagawa H, Fushida S, Ahmed
AK, et al: Low-dose gemcitabine induces major histocompatibility
complex class I-related chain A/B expression and enhances an
antitumor innate immune response in pancreatic cancer. Clin Exp
Med. 17:19–31. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kondo M, Izumi T, Fujieda N, Kondo A,
Morishita T, Matsushita H and Kakimi K: Expansion of human
peripheral blood γδ T cells using zoledronate. J Vis Exp. pii:3182.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tatsumi T, Takehara T, Yamaguchi S,
Sasakawa A, Sakamori R, Ohkawa K, Kohga K, Uemura A and Hayashi N:
Intrahepatic delivery of alpha-galactosylceramide-pulsed dendritic
cells suppresses liver tumor. Hepatology. 45:22–30. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lu J, Aggarwal R, Kanji S, Das M, Joseph
M, Pompili V and Das H: Human ovarian tumor cells escape γδ T cell
recognition partly by down regulating surface expression of MICA
and limiting cell cycle related molecules. PLoS One. 6:e233482011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu J, Groh V and Spies T: T cell antigen
receptor engagement and specificity in the recognition of
stress-inducible MHC class I-related chains by human epithelial
gamma delta T cells. J Immunol. 169:1236–1240. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Marchion D and Münster P: Development of
histone deacetylase inhibitors for cancer treatment. Expert Rev
Anticancer Ther. 7:583–598. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Catalano MG, Fortunati N, Pugliese M,
Costantino L, Poli R, Bosco O and Boccuzzi G: Valproic acid induces
apoptosis and cell cycle arrest in poorly differentiated thyroid
cancer cells. J Clin Endocrinol Metab. 90:1383–1389. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Phiel CJ, Zhang F, Huang EY, Guenther MG,
Lazar MA and Klein PS: Histone deacetylase is a direct target of
valproic acid, a potent anticonvulsant, mood stabilizer, and
teratogen. J Biol Chem. 276:36734–36741. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Blaheta RA and Cinatl J Jr: Anti-tumor
mechanisms of valproate: A novel role for an old drug. Med Res Rev.
22:492–511. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Göttlicher M, Minucci S, Zhu P, Krämer OH,
Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG
and Heinzel T: Valproic acid defines a novel class of HDAC
inhibitors inducing differentiation of transformed cells. EMBO J.
20:6969–6978. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang F, Shao Y, Yang F, Liu M, Huang J,
Zhu K, Guo C, Luo J, Li W, Yang B, et al: Valproic acid upregulates
NKG2D ligand expression and enhances susceptibility of human renal
carcinoma cells to NK cell-mediated cytotoxicity. Arch Med Sci.
9:323–331. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shi P, Yin T, Zhou F, Cui P, Gou S and
Wang C: Valproic acid sensitizes pancreatic cancer cells to natural
killer cell-mediated lysis by upregulating MICA and MICB via the
PI3K/Akt signaling pathway. BMC Cancer. 14:3702014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Takikawa T, Masamune A, Hamada S, Nakano
E, Yoshida N and Shimosegawa T: miR-210 regulates the interaction
between pancreatic cancer cells and stellate cells. Biochem Biophys
Res Commun. 437:433–439. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bonneville M, O'Brien RL and Born WK:
Gammadelta T cell effector functions: A blend of innate programming
and acquired plasticity. Nat Rev Immunol. 10:467–478. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Todaro M, Meraviglia S, Caccamo N, Stassi
G and Dieli F: Combining conventional chemotherapy and γδ T
cell-based immunotherapy to target cancer-initiating cells.
Oncoimmunology. 2:e258212013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Schüler S, Fritsche P, Diersch S, Arlt A,
Schmid RM, Saur D and Schneider G: HDAC2 attenuates TRAIL-induced
apoptosis of pancreatic cancer cells. Mol Cancer. 9:802010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bai J, Sui J, Demirjian A, Vollmer CM Jr,
Marasco W and Callery MP: Predominant Bcl-XL knockdown disables
antiapoptotic mechanisms: Tumor necrosis factor-related
apoptosis-inducing ligand-based triple chemotherapy overcomes
chemoresistance in pancreatic cancer cells in vitro. Cancer Res.
65:2344–2352. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Laheru D, Lutz E, Burke J, Biedrzycki B,
Solt S, Onners B, Tartakovsky I, Nemunaitis J, Le D, Sugar E, et
al: Allogeneic granulocyte macrophage colony-stimulating
factor-secreting tumor immunotherapy alone or in sequence with
cyclophosphamide for metastatic pancreatic cancer: A pilot study of
safety, feasibility, and immune activation. Clin Cancer Res.
14:1455–1463. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen G and Emens LA: Chemoimmunotherapy:
Reengineering tumor immunity. Cancer Immunol Immunother.
62:203–216. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Salih HR, Rammensee HG and Steinle A:
Cutting edge: Down-regulation of MICA on human tumors by
proteolytic shedding. J Immunol. 169:4098–4102. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chitadze G, Lettau M, Bhat J, Wesch D,
Steinle A, Fürst D, Mytilineos J, Kalthoff H, Janssen O, Oberg HH
and Kabelitz D: Shedding of endogenous MHC class I-related chain
molecules A and B from different human tumor entities:
Heterogeneous involvement of the ‘a disintegrin and
metalloproteases’ 10 and 17. Int J Cancer. 133:1557–1566. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jinushi M, Takehara T, Tatsumi T,
Hiramatsu N, Sakamori R, Yamaguchi S and Hayashi N: Impairment of
natural killer cell and dendritic cell functions by the soluble
form of MHC class I-related chain A in advanced human
hepatocellular carcinomas. J Hepatol. 43:1013–1020. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yamanegi K, Yamane J, Kobayashi K, Ohyama
H, Nakasho K, Yamada N, Hata M, Fukunaga S, Futani H, Okamura H and
Terada N: Downregulation of matrix metalloproteinase-9 mRNA by
valproic acid plays a role in inhibiting the shedding of MHC class
I-related molecules A and B on the surface of human osteosarcoma
cells. Oncol Rep. 28:1585–1590. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yamanegi K, Yamane J, Kobayashi K,
Kato-Kogoe N, Ohyama H, Nakasho K, Yamada N, Hata M, Fukunaga S,
Futani H, et al: Valproic acid cooperates with hydralazine to
augment the susceptibility of human osteosarcoma cells to Fas- and
NK cell-mediated cell death. Int J Oncol. 41:83–91. 2012.PubMed/NCBI
|
|
44
|
Lee KH, Choi EY, Kim MK, Kim KO, Jang BI,
Kim SW, Kim SW, Song SK and Kim JR: Inhibition of histone
deacetylase activity down-regulates urokinase plasminogen activator
and matrix metalloproteinase-9 expression in gastric cancer. Mol
Cell Biochem. 343:163–171. 2010. View Article : Google Scholar : PubMed/NCBI
|
